Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20245295 | 1.00 | KDM4E (0.46) | KDM4EALDH1A1ALOX15MEN1KMT2A | |
| SCHEMBL14313611 | 1.00 | KDM4E (0.46) | KDM4EALDH1A1ALOX15MEN1KMT2A | |
| SCHEMBL736959 | 0.94 | KDM4E (0.46) | KDM4EALDH1A1ALOX15MEN1KMT2A | |
| SCHEMBL9557835 | 0.94 | KDM4E (0.46) | KDM4EALDH1A1ALOX15MEN1KMT2A | |
| SCHEMBL736459 | 0.94 | KDM4E (0.46) | KDM4EALDH1A1ALOX15MEN1KMT2A | |
| SCHEMBL14175057 | 0.92 | KDM4E (0.44) | KDM4EALDH1A1ALOX15MEN1KMT2A | |
| SCHEMBL3688411 | 0.92 | KDM4E (0.44) | KDM4EALDH1A1ALOX15MEN1KMT2A | |
| SCHEMBL737910 | 0.92 | KDM4E (0.44) | KDM4EALDH1A1ALOX15MEN1KMT2A | |
| SCHEMBL736102 | 0.92 | KDM4E (0.44) | KDM4EALDH1A1ALOX15MEN1KMT2A | |
| SCHEMBL18976856 | 0.88 | KDM4E (0.53) | KDM4EALDH1A1ALOX15MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023142754-A1 | EZH1/2 INHIBITOR, PREPARATION THEREOF, AND USE THEREOF IN ANTI-TUMOR THERAPY | 江苏天士力帝益药业有限公司 | 2023-08-03 | — | — | WO | disclosed |
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20090209511-A1 | Benzofuran Derivatives | KAWAGUCHI TAKAYUKI | 2009-08-20 | — | — | US | disclosed |
| US-20090209511-A1 | Benzofuran Derivatives | KAWAGUCHI TAKAYUKI | 2009-08-20 | — | — | US | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | KDM4E 3977/4885ALDH1A1 422/4885ALOX15 617/4885 |
| US-20090209511-A1 | Benzofuran Derivatives | F12, F2, F3 | KDM4E 1464/4885ALDH1A1 693/4885ALOX15 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.